Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer

Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer

Background and purpose: The response of human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer to HER2 targeted neoadjuvant therapy is significant. However, the response is not uniform, and a proportion of patients respond poorly. This study aimed to identify predictors of r...

Full description

Bibliographic Details
Main Author:	LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Format:	Article
Language:	English
Published:	Editorial Office of China Oncology 2022-05-01
Series:	Zhongguo aizheng zazhi
Subjects:	\|human epidermal growth factor receptor 2 heterogeneity\|breast cancer\|neoadjuvant therapy
Online Access:	http://www.china-oncology.com/fileup/1007-3639/PDF/1654759392696-995282893.pdf

Similar Items

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
by: Jiuyan Shang, et al.
Published: (2023-02-01)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
by: Gavin P. Dowling, et al.
Published: (2023-01-01)

Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
by: Wei Chen, et al.
Published: (2023-10-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
by: Fu Li, et al.
Published: (2023-01-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
by: WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng
Published: (2023-07-01)

The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
by: LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun
Published: (2023-04-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Study the technical validity and feasibility of serum HER-2/Neu and its correlation with tissue HER-2 status in female breast cancer patients only
by: Sufia Ahmad Khan, et al.
Published: (2023-11-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Investigation of Tumor Heterogeneity Using Integrated Single-Cell RNA Sequence Analysis to Focus on Genes Related to Breast Cancer-, EMT-, CSC-, and Metastasis-Related Markers in Patients with HER2-Positive Breast Cancer
by: Sho Shiino, et al.
Published: (2023-09-01)

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer
by: Ulrika Pellas, et al.
Published: (2023-07-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
by: Abdullah Evren YETİŞİR, et al.
Published: (2021-08-01)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
by: Kaho Tateishi, et al.
Published: (2023-11-01)

Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: María del Pilar Chantada-Vázquez, et al.
Published: (2022-02-01)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
by: Hai-long Chen, et al.
Published: (2023-09-01)

Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment
by: V. O. Bashlyk, et al.
Published: (2018-07-01)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
by: Daniel Rayson, et al.
Published: (2022-12-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
by: Shuling Zhou, et al.
Published: (2023-02-01)

Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Agampodi Danushi M. Gunasekara, et al.
Published: (2022-01-01)

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
by: Jun Cao, et al.
Published: (2023-08-01)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
by: Natalia Krawczyk, et al.
Published: (2022-06-01)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
by: Nandini Dey, et al.
Published: (2021-01-01)

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
by: Marta Piras, et al.
Published: (2021-05-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
by: Jiujun Zhu, et al.
Published: (2022-09-01)

Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
by: Lu Liu, et al.
Published: (2023-12-01)

Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
by: Xueying Wu, et al.
Published: (2022-01-01)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
by: Tresa M. McGranahan, et al.
Published: (2022-10-01)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
by: Cristiano Ferrario, et al.
Published: (2022-04-01)

PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
by: Xiaoyu Liu, et al.
Published: (2023-09-01)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
by: Jiayi Li, et al.
Published: (2022-02-01)

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer
by: Qiyun Shi, et al.
Published: (2023-12-01)

Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer
by: Yong-Seok Kim, et al.
Published: (2022-07-01)

Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
by: Youzhao Ma, et al.
Published: (2023-05-01)

<sup>89</sup>Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study
by: D. G. J. Linders, et al.
Published: (2023-10-01)

HS‐10352 in hormone receptor‐positive, HER2‐negative advanced breast cancer: A phase 1 dose‐escalation trial
by: Quchang Ouyang, et al.
Published: (2023-12-01)

MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer
by: Almir G.V. Bitencourt, et al.
Published: (2020-11-01)